

A G E N D A

2nd International Thoracic Oncology Congress Dresden (2nd ITOCD)
September 16-18, 2010, Advances through Molecular Biology in Thoracic
Cancer

Congress Venue: The Westin Bellevue Hotel & Congress Center Dresden,
Große Meissner Straße 15, 01097 Dresden, Germany

Registration:

Delegates Helping Desk (Westin Bellevue Dresden -Congress Center)

Opening Hours :

September 15, 2010	02:00 p.m. – 10:00 p.m.
September 16, 2010 - September 18, 2010	07:30 a.m. – 06:00 p.m.

Thursday, September 16, 2010

08:00 – 08:45 Meet the Professor Session

1. Management of bone metastasis; P. Harper, London
2. Tumor pathology: pathological diagnosis and molecular analysis; M. Papotti, Torino

08:45 – 09:15 Opening remarks

Targeting Tumor Angiogenesis: Molecular Biology and Clinical Practice

Chairs: R. Herrmann, Basel / N. Saijo, Tokyo

09:15 – 09:30 Biomarkers profile and clinical factors in selecting patients
A.B. Sandler, Portland

09:30 – 09:45 Imaging in targeted therapy
C. Fink, Mannheim

09:45 – 10:00 Management of toxicity of anti-angiogenic/anti-EGFR agents
J. Heymach, Houston

10:00 – 10:15 Integrin inhibitors
S. Peters, Lausanne

10:15 – 10:30 Vascular disrupting agents
J.Y. Doulliard, Nantes

10:30 – 10:45 Anti-angiogenic TKI's
U. Gatzemeier, Großhansdorf

10:45 – 11:15 Molecular biology
E. Voest, Utrecht

11:15 – 11:30 Discussant: M. Kris, New York

11:30 – 12:00 BREAK

12:00 – 13:00 Boehringer-Ingelheim Satellite Symposium

EGFR/HER2 and Triple Angiokinase Inhibition (TAI): personalised and targeted approaches in NSCLC

Chairs: T. J. Lynch, New Haven / C. Manegold, Mannheim

1. State of the art: biological markers in NSCLC and their clinical implications
R. Rosell, Barcelona
2. Overcoming resistance to 1st generation EGFR-TKI: new therapeutic option on the horizon
W. Eberhardt, Essen
3. Multikinase inhibition: there is more than VEGF
C. Grohé, Berlin

13:00 – 13:30 BREAK

13:30 – 14:30 F. Hoffmann La-Roche Satellite Symposium

Treatment strategies to extend survival in advanced NSCLC

Chair: U. Gatzemeier, Großhansdorf

1. Anti-VEGF: a fundamental therapeutic approach in NSCLC
U. Gatzemeier, Großhansdorf
2. Predicting bevacizumab efficacy using clinical markers: the evidence to date
A. Sandler, Portland
3. EGFR mutations in NSCLC: key insights and advances
L. Paz-Ares, Seville
4. Beyond first-line treatment: expanding the options
G. V. Scagliotti, Torino

Thursday, September 16, 2010

Novel Agents (1)

Chairs: W. Eberhardt, Essen / T. Le Chevalier, Paris

14:45 – 15:00 Heat shock protein targeting agents
K. O'Byrne, Dublin

15:00 – 15:15 Histone deacetylase inhibitors
S. Ramalingam, Atlanta

15:15 – 15:30 PARP1-inhibitors
J.-J. Soria, Paris

15:30 – 15:45 Dendritic cell recruiters and activators
A. Y. Chang, Singapore

15:45 – 16:00 Vaccine therapy
J. Vansteenkiste, Leuven

16:00 – 16:15 Pro-apoptotic agents
F. R. Khuri, Atlanta

16:15 – 16:30 Discussant: G. Giaccone, Bethesda

19:30 - 23:00 Faculty Dinner

Friday, September 17, 2010

08:00 – 08:45 Mannheim Lilly Oncology Lecture

Targeted therapy: how to clinically develop new agents and treatment strategies based on pre-clinical information
P. Bunn, Denver

**Targeting the Epidermal Growth Factor Receptor (EGFR):
Molecular Biology and Clinical Practice**

Chairs: N.Thatcher, Manchester / K. Syrigos, Athens

09:00- 09:30 Molecular biology of the EGFR-pathway
A. F. Gazdar, Dallas

09:30 - 09:45 Clinical and molecular predictors of EGFR-TKI sensitivity
F. A. Shepherd, Toronto

09:45 – 10:00 Mechanism of drug resistance and how to overcome first generation EGFR-TKI failure
P. A. Jänne, Boston

10:00 – 10:15 EGFR-TKI first-line therapy: diagnostic assessment and drug selection
T. Mok, Hong Kong

10:15 – 10:30 EGFR-assessment in prospective clinical trials
R. Dziadziusko, Gdansk

10:30 – 10:45 Treatment duration and sequencing of EGFR-TKI inhibitors
F. Cappuzzo, Livorno

10:45 – 11:00 EGFR-targeting antibodies: clinical and molecular sensitivity predictors
R. Pirker, Vienna

11:00 – 11:15 EGFR-targeting antibodies in combination with radiotherapy
F. Mornex, Lyon

11.15 – 11.30 Discussant: T.J. Lynch, New Haven

11:30 – 12:00 BREAK

12:00 – 13:00 Presidential Symposium

NSCLC: Relevance of Treatment Prediction by Histology for Early and Advanced Disease

Chairs: F. Blackhall, Manchester / C. Manegold, Mannheim

1. Relevance of TS testing: British experience
K. Kerr, Aberdeen
2. Pharmacogenomic guided treatment strategies for early NSCLC
G. V. Scagliotti, Torino
3. Pemetrexed (Alimta therapy): duration and frequency
C. Belani, Hersey

13.30 – 14.30 Merck Serono Satellite Symposium Combination is Key – Targeted Strategies against Lung Cancer

Chairs: C. Butts, Edmonton / J.-Y. Douillard, Nantes

1. Therapeutic cancer vaccines
F. Shepherd, Toronto
2. The EGFR-antibody in NSCLC
R. Pirker, Vienna
3. Integrin inhibitors: a new class of targeted therapies in NSCLC
K. O'Byrne, Dublin

Friday, September 17, 2010

Gene Expression/Tumor Histology Guided Therapy

Chairs: N. van Zandwijk, Sydney / J. Niklinski, Bialystok

14.45 – 15.15 Molecular basis

H. Allgayer, Mannheim

15.15 – 15.30 Proteomics and outcome prediction

D. P. Carbone, Nashville

15.30 – 15.45 Genomic signatures and prediction for diagnosis and outcome

A. Potti, Durham

15.45 – 16:00 MicroRNA signatures and outcome prediction

P.-C. Yang, Taiwan

16:00 – 16:15 TS-expression and sensitivity to anti-folates

G. V. Scagliotti, Torino

16.15 – 16:30 ERCC1, RRM1, and BRCA1-gene expression and outcome prediction

G. Bepler, Detroit

16:30 – 16:45 Tumor histology and clinical outcome

C. Manegold, Mannheim

16:45 – 17:00 Discussant: K. Kerr, Aberdeen

19:30 Grand Evening Event

Saturday, September 18, 2010

08:00 – 08:45 Meet the Professor Session

1. Management of bone metastasis; P. Harper, London
2. Tumor pathology: pathological diagnosis and molecular analysis
M. Papotti, Torino

Novel Agents (2)

Chairs: P. Postmus, Amsterdam / J. S. Lee, Seoul

09:00 – 09:15 ACT, MAPK, MEK-inhibitors
A. Adjei, Buffalo

09:15 – 09:30 ALK, MET-inhibitors
R. Stahel, Zürich

09:30 – 09:45 SRC-targeting agents
O. Gautschi, Bern

09:45 – 10:00 m-Tor-inhibitors
L. Crinò, Perugia

10:00 – 10:15 Insulin growth factor receptor targeting agents
L. Paz-Ares, Sevilla

10:15 – 10:30 Discussant: G. Goss, Ottawa

10.30 – 11.00 BREAK

Saturday, September 18, 2010

Tabacco Control and Lung Cancer Prevention
(supported by an Eli-Lilly unrestricted educational grant)

Chairs: L.R. Pilz, Heidelberg / K. Park, Seoul

11:00 – 11:15 WHO perspectives in reducing lung cancer mortality
A. Ullrich, Geneva

11:15 – 11:30 Tobacco control policy in Poland
J. Jassem, Gdansk

11:30 – 11:45 Smoking cessation in women
C. M. Dresler, Littler Rock

11:45 – 12:00 Female gender as a prognostic and predictive factor
S. Novello, Torino

12:00 – 12:15 New targets for chemoprevention
Y. E. Miller, Denver

12:15 – 12:30 Chemoprevention of high risk patient populations
N. van Zandwijk, Sydney

12:30 – 12:45 Discussant: P. Boffetta, New York

12:45 – 14:00 BREAK

Saturday, September 18, 2010

2010 Challenges in Thoracic Oncology (I)

Chairs: D. H. Grunenwald, Paris / C. Zhou, Shanghai

14:15 – 14:30 Implications of the new TNM system for the surgical management of early stage lung cancer
P. Goldstraw, London

14:30 - 14:45 Implications of the new TNM system for modern imaging
S. Schönberg, Mannheim

14.45 - 15.00 Minimally invasive non-surgical methods for staging lung cancer
F. Herth, Heidelberg

15:00 – 15:10 Adjuvant chemotherapy
B. Besse, Paris

15:10 – 15:20 Induction chemotherapy
P. van Schil, Antwerp

15:20 – 15:35 Advanced NSCLC: maintenance therapy
C. Belani, Hersey

15:35 – 16:00 BREAK

Saturday, September 18, 2010

2010 Challenges in Thoracic Oncology (II)

Chairs: P. Hohenberger, Mannheim / E. Smit, Amsterdam

16:00 – 16:15 Stereotactic radiation therapy for stage I NSCLC
F. Wenz, Mannheim

16:15 – 16:30 Chemo-radiation
D. de Ruyscher, Maastricht

16:30 – 16:45 Is thymic carcinoma a specific entity?
A. Marx, Mannheim

16:45 - 17:00 Malignant pleural mesothelioma: extension of surgery
W. Weder, Zurich

17.00 - 17.15 Malignant pleural mesothelioma: new drug development
D. Fennell, Belfast

17:15 – 17:30 SCLC: Combined modality therapy in limited stage disease
A. Ardizzoni, Parma

17:30 -17:45 End of the Conference: Closing Remarks